Shen Cailu, Zhang Siying, Wang Xiaoli, Shen Di, Ge Xiaosong, Mao Yong
Department of Cancer Diagnosis and Treatment Center, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu 214000, P.R. China.
Wuxi Medical College of Jiangnan University, Wuxi, Jiangsu 214000, P.R. China.
Mol Clin Oncol. 2025 Jul 4;23(3):81. doi: 10.3892/mco.2025.2876. eCollection 2025 Sep.
The present study evaluated therapeutic strategies and clinical outcomes in Chinese patients with mesenchymal-epithelial transition () alterations in non-small cell lung cancer (NSCLC) who were progressing on epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), aiming to address the unmet need of overcoming -driven resistance. A real-world study was conducted, involving eligible patients with NSCLC treated at Jiangnan University Affiliated Hospital between February 2022 and April 2024. Based on the treatment regimen, patients were categorized into three groups: MET-TKI combined with EGFR-TKI, chemotherapy-based regimen, and other regimens. The primary outcomes were the objective response rate (ORR), time to treatment failure (TTF), post-progression survival (PPS) and adverse events (AEs). A total of 32 patients were included in the analysis. The MET-TKI plus EGFR-TKI group (n=10) achieved the highest ORR at 55.6%, followed by the chemotherapy-based regimen group (n=15) at 42.9% and the other regimens group (n=7) at 14.3%. The median TTF was 9.5 months for the MET-TKI plus EGFR-TKI group, compared with 4.4 and 3.6 months for the chemotherapy-based and other regimens groups, respectively (P=0.748). Similarly, the median PPS was 14.4 months in the MET-TKI plus EGFR-TKI group, compared with 9.4 and 7.0 months in the chemotherapy-based and other regimens groups, respectively (P=0.733). Treatment-related AEs varied among the groups, with nausea, peripheral edema and rash being the most common in the MET-TKI plus EGFR-TKI group. In conclusion, the combination of MET-TKI and EGFR-TKI demonstrates promising benefits in terms of TTF, PPS and ORR, underscoring its potential as a viable treatment option. The modest improvements observed, coupled with the inherent limitations of the present study, emphasize the necessity for further research to optimize treatment strategies and gain a deeper understanding of the long-term efficacy of combination therapy in addressing -driven resistance to EGFR-TKI.
本研究评估了非小细胞肺癌（NSCLC）中发生间充质-上皮转化（MET）改变且在表皮生长因子受体-酪氨酸激酶抑制剂（EGFR-TKI）治疗期间病情进展的中国患者的治疗策略和临床结局，旨在满足克服MET驱动的耐药性这一未被满足的需求。开展了一项真实世界研究，纳入2022年2月至2024年4月期间在江南大学附属医院接受治疗的符合条件的NSCLC患者。根据治疗方案，患者被分为三组：MET-TKI联合EGFR-TKI组、基于化疗的方案组和其他方案组。主要结局指标为客观缓解率（ORR）、治疗失败时间（TTF）、进展后生存期（PPS）和不良事件（AE）。共有32例患者纳入分析。MET-TKI加EGFR-TKI组（n = 10）的ORR最高，为55.6%，其次是基于化疗的方案组（n = 15），为42.9%，其他方案组（n = 7）为14.3%。MET-TKI加EGFR-TKI组的中位TTF为9.5个月，而基于化疗的方案组和其他方案组分别为4.4个月和3.6个月（P = 0.748）。同样，MET-TKI加EGFR-TKI组的中位PPS为14.4个月，而基于化疗的方案组和其他方案组分别为9.4个月和7.0个月（P = 0.733）。治疗相关AE在各组中有所不同，MET-TKI加EGFR-TKI组中恶心、外周水肿和皮疹最为常见。总之，MET-TKI与EGFR-TKI联合使用在TTF、PPS和ORR方面显示出有前景的益处，突出了其作为一种可行治疗选择的潜力。观察到的适度改善，加上本研究的固有局限性，强调了进一步研究以优化治疗策略并更深入了解联合治疗在克服MET驱动的EGFR-TKI耐药性方面的长期疗效的必要性。
